SIRNAOMICS-B (02257): Partially completed the subscription of new shares under general authorization and terminated the subscription agreement.
Shengnuo Medicine-B (02257) announced that Subscription Agreement B was partially completed on December 7, 2025, and issued 1.0037 million new shares to Subscriber B at a subscription price of HK$12.00 per share.
SIRNAOMICS-B (02257) announced that the subscription agreement B was partially completed on December 7, 2025, and 1,003,700 new shares were issued to subscriber B at a subscription price of HK$12.00 per share.
After friendly and honest negotiations, the company and subscriber B agreed to terminate the subscription of the remaining 2,151,300 shares on December 7, 2025. Following this termination, all rights and obligations of the contracting parties will cease, and neither party can make any claims against the other regarding subscription agreement B. The board believes that terminating the subscription of the remaining shares will not have any significant adverse impact on the company's existing business, operations, or financial condition.
Subscriber C failed to fulfill the responsibilities specified in subscription agreement C before December 7, 2025, and the company has terminated the agreement in accordance with its terms. After this termination, all rights and obligations of the contracting parties will cease, and neither party can make any claims against the other regarding subscription agreement C. The board believes that terminating subscription agreement C will not have any significant adverse impact on the company's existing business, operations, or financial condition.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th
Jiangsu Hengrui Pharmaceuticals (01276) has adjusted 20 products/indications to the new national medical insurance list. Among them, 10 products are included for the first time.

CHINA BOTON (03318) will be suspended from trading starting December 8th for a short period, awaiting the announcement of a significant sale transaction.

GMTEight List of A-share restricted sales and lifting restrictions | December 8th






